Dilmapimod (100, CAS 444606-18-2) is a p38 MAP-kinase inhibitor patented by SmithKline Beecham Corporation (GSK-681323) in 2001 and was used in clinical studies for inflammation, neuropathic pain, and cardiac problems but was eventually ceased due to liver damage.16 Clinical research examined TAK-733 (101, CAS 1035555-63-5), a MEK1 and MEK2 (MEK1/2) inhibitor, for advanced non-hematologic malignancies, including metastatic melanoma. Here, MAP2K1 is linked to metastatic melanoma.